What predicts whether psychedelics will work well for depression? Primarily what happens during the session.

There is a new scientific article that maps out which factors may predict whether psychedelic therapy works well for depression.

In it, we discuss:

The authors conducted a scoping review of predictors and moderators of antidepressant response to classic serotonergic psychedelics administered with psychotherapeutic support to adults with depressive disorders, including treatment-resistant depression. To this end, they searched multiple major databases and trial registries and included randomized studies, open-label studies, and naturalistic cohorts. In total, they included 48 studies.

The real focus of this article is not on a single new clinical experiment, but on the question of which factors are most consistently associated with improvement. According to the review, process factors during the dosing session prove to be the most predictive. Greater emotional breakthrough, mystical or unitary experiences, and ego dissolution coupled with reappraisal or insight were generally associated with greater and more sustained reduction in depressive symptoms. Anxiety-dominated or dysphoric experiences, on the other hand, were more frequently associated with less benefit.

It also clearly emerges that set and setting are important. A stronger therapeutic alliance and music perceived as appropriate or resonant predicted not only the earlier occurrence of therapeutically relevant acute experiences, but also later clinical gain. In doing so, this review supports the idea that not only the material matters, but also the context in which the session takes place.

According to the authors, baseline patient characteristics were much less convincing as predictors. Demographic characteristics were usually not informative. PTSD comorbidity appeared in some studies to be associated with weaker treatment trajectories, and extensive prior psychedelic experience was sometimes associated with smaller additional improvements. In general, therefore, static characteristics seem less important than what happens during the session and in the guidance.

The review also discusses biological indicators associated with better outcomes. More favorable responses were linked, among other things, to signals consistent with greater neural flexibility and neuroplasticity, such as less segregated network dynamics and certain EEG indices, alongside peripheral changes pointing to the involvement of neurotrophic, inflammatory, and HPA axis-related processes.

It is important, however, that this is a scoping review and not a meta-analysis with a single hard effect estimate. The authors themselves emphasize that the included studies differed significantly in measurement methods, analytical frameworks, and robustness. Their conclusion is therefore primarily practical: those wishing to optimize psychedelic therapy should focus mainly on good preparation, a therapeutic alliance, appropriate music, facilitating emotional breakthrough and meaning-making, and limiting anxious dysregulation.

In one sentence: this article shows that the success of psychedelic therapy for depression likely depends less on fixed patient characteristics and more on what happens during the session and how well the context is aligned with it.